# Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer

> **NCT00098852** · PHASE2 · UNKNOWN · sponsor: **University of California, San Francisco** · enrollment: 25 (estimated)

## Conditions studied

- Head and Neck Cancer

## Interventions

- **DRUG:** rosiglitazone maleate

## Key facts

- **NCT ID:** NCT00098852
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2004-10
- **Primary completion:** 2010-06
- **Final completion:** —
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2014-01-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00098852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00098852, "Rosiglitazone in Treating Patients With Locoregionally Extensive or Metastatic Thyroid Cancer". Retrieved via AI Analytics 2026-07-19 from https://api.ai-analytics.org/clinical/NCT00098852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*